The Inhibition Of Alantolactone On Human Ovarian Cancer Skov-3 And A2780 Cells

PUPROSE:The present study investigates the effect of alantolactone on the proliferation, apoptosis, cell cycle and the production of cytokine IL-6, IL-8 and VEGF of human ovarian cancer cells A2780 and Skov3. Besides, we also investigate the medical mechanism of alantolactone acting on A2780 and Skov3 when it combines with paclitaxel in order to test whether alantolactone can work as the sensitizer to the resistance to paclitaxel. In addition, whether alantolactone can work effectively in the adjuvant therapy of ovarian cancer for patients with chemotherapy intolerance would be tested.METHODS:1. We detect the viability of ovarian cancer cells treated with alantolactone and alantolactone combine with paclitaxel by tetramethyl-azocolorimetry.2. To research the cycle distribution of ovarian cancer cells treated with alantolactone in gradient concentrations for 24 hours and the apoptosis that induced by a certain concentration of alantolactone for 15 and 30 hours, we adopt the flow cytometer..3. By means of enzyme-linked immunosorbent assay, we test the production of cytokine IL-6, IL-8 and VEGF of human ovarian cancer cells A2780 and Skov3.RESULTS:1. The drug concentration interval of AL effecting on human ovarian cancer cells is 1μmol/L to 100μmol/L. The inhibition is positively correlated with the concentration of the alantolactone. Within the increase of alantolactone concentration, the viability goes down. Whether the chemotherapy with paclitaxel is combined with alantolactone or not, the cell killing effecting on Skov3 is almost the same.2. After mediated by alantolactone, the cells decreased in G1 phase and increased in G2/M phase. The retardation looks more obvious while concentration increases.3. The induce of alantolactone makes the apoptosis rate running up, which becomes strengthened as time goes on.4. Both IL-6 and IL-8 secreted by Skov3 treated with alantolactone and paclitaxel decrease while we find there is no function on A2780. At the same time, the secretion of VEGF descends whether Skov3 or A2780 is induced by the combination of costulactone and paclitaxel.CONCLUSION:1. Alantolactone had cytotoxicity on human ovarian cancer cells A2780 and Skov3. Whether the chemotherapy with paclitaxel is combined with alantolactone or not, the cell killing effecting on Skov3 is almost the same.2. Cell cycle arrest in human ovarian cancer cells A2780 and Skov3 can be induced obviously by certain concentration of alantolactone. This cell cycle arrest mediated by alantolactone is similar to the one mediated by paclitaxel.3. Alantolactone can make apoptotic effect on human ovarian cancer cells A2780 and Skov3.4. Alantolactone can decrease the proinflammatory factor secreted by A2780 and Skov3 which treated with paclitaxel.